InsiderTrades

Form 4 for JBIO Jade Biosciences, Inc.

Accepted 2024-03-27 00:00:00 ET · period of report 2024-03-25 · accession 0001415889-24-009243 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2024-03-27 2024-03-25 JBIO Dake Benjamin T SEE REMARKS M - OptEx $10.61 +3,432 4,723 +266% +$36.4K
D 2024-03-27 2024-03-25 JBIO Dake Benjamin T SEE REMARKS S - Sale+OE $28.01 -3,432 1,291 -73% -$96.1K
D 2024-03-27 2024-03-25 JBIO Dake Benjamin T SEE REMARKS M - OptEx $0.00 -3,432 40.1K -8% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-03-25 M A 3,432 $10.61 4,723 D — —
2 Common Common Stock 2024-03-25 S D 3,432 $28.01 1,291 D — — (F2) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.95 to $28.385, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
3 Derivative Stock Option (Right to Buy) 2024-03-25 M D 3,432 $0.00 40,068 D $10.61 · — to 2031-12-13 3,432 Common Stock (F3) A total of 58,000 shares subject to an employee stock option were granted on December 14, 2021, with the first installment vested on January 14, 2022, and with shares vesting in 48 substantially equal monthly installments.